October 10, 2011
Novartis Pharma announced on September 26 that it has obtained approval for Ilaris 150 mg for SC Injection (canakinumab), the first drug approved in Japan for the treatment of cryopyrin-related periodic syndromes (CAPS), a group of rare and debilitating autoinflammatory...read more